Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dexpramipexole

- PMLiVE

Merck & Co drops Parkinson’s prospect preladenant

No better than placebo during phase III trial

- PMLiVE

Lilly abandons tabalumab for rheumatoid arthritis

Decision based on lack of efficacy in late-stage trials

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

- PMLiVE

Upcoming treatments for amyotrophic lateral sclerosis

While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed

- PMLiVE

Publicis Amsterdam wins Effie Award Silver for Dutch ALS Foundation

Hard-hitting campaign for amyotrophic lateral sclerosis (ALS) puts up sterling fight for sufferers

- PMLiVE

GSK discontinues development of Anacor antibiotic

Patients developed resistance to compound during trial

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

- PMLiVE

Novo drops late-stage haemophilia candidate vatreptacog alfa

Patients developed anti-drug antibodies during phase III clinical trial

- PMLiVE

Targacept to cut more jobs after ADHD trial failure

TC-5619 disappoints in phase II trial after missing primary endpoint

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links